New partnership aims to put epigenetic testing directly into the hands of consumers, with providers likely next in line.
TruDiagnostic, already well known for its methylation and epigenetic biomarker testing, has partnered with Infinite Epigenetics to expand access beyond clinics and research settings and into consumers’ homes.
Infinite Epigenetics, currently in beta and operating a wait list model, offers at-home membership packages that combine quarterly blood testing with epigenetic analysis of over a million DNA methylation sites. The service is pitched as a “personalized playbook” for health – consumers receive insights on aging speed, disease risk, immune resilience and other healthspan markers, all delivered via a digital dashboard.
In a promotional video, Infinite promises to “catch disease before symptoms arise”, helping its customers to “live longer, sleep better and feel stronger”. It is a consumer-first manifesto that reflects a growing trend in longevity – moving tools once reserved for academic labs into the hands of paying subscribers.
Power to the people
This is where TruDiagnostic’s role is key. The company has built a reputation for its wide panel of epigenetic clocks and biomarker proxies, and for its collaborations with academic and commercial partners. Partnering with Infinite effectively repackages that science for a direct-to-consumer audience – quarterly testing, simplified insights and physician-guided recommendations delivered without clinic visits.
For consumers, the appeal is clear: regular, data-rich updates on their biological age and health trajectories, without needing to go through providers or research programs. The potential drawback is also clear: the science of epigenetic biomarkers is advancing, but questions remain over reproducibility, interpretation, and how much actionable benefit an individual can derive from quarterly biological age scores. Nevertheless, Infinite’s model reflects a strong demand for proactive health tools – and suggests that longevity testing is moving from boutique to mainstream.
The provider market has not been forgotten. In her LinkedIn post announcing the partnership, TruDiagnostic Cofounder Hannah Went acknowledged that while Infinite is focused on consumer access today, “you can expect that TruDiagnostic may be exploring ways to bring aspects of this offering into the provider channel in the future.” For clinicians already using TruDiagnostic’s research-grade panels, that hint will be worth watching.
For TruDiagnostic and Infinite, the benefits are not only commercial but scientific. Scaling testing through a consumer membership model could generate vast amounts of anonymized longitudinal data – repeated measures from thousands of individuals over years. Such datasets could sharpen the performance of epigenetic clocks, enable the discovery of new biomarker proxies and provide a living laboratory for studying how lifestyle and interventions alter biological aging in real time. The promise of ‘healthspan for the masses’ may therefore extend beyond individual dashboards to accelerating the field itself.
Democratizing access to longevity testing is an ambitious promise; handing data and dashboards directly to consumers democratizes access, but it also shifts responsibility. Whether Infinite’s membership model proves sustainable, and whether consumers translate epigenetic scores into meaningful lifestyle changes, will determine how much of that promise is realized. What is clear is that longevity testing is leaving the lab and landing firmly in people’s hands.
